Advertisement
U.S. Markets open in 7 hrs 16 mins

enGene Holdings Inc. (ENGN)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
16.19-0.08 (-0.49%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close16.27
Open15.82
Bid15.61 x 100
Ask16.68 x 100
Day's Range15.00 - 16.52
52 Week Range6.69 - 47.17
Volume86,623
Avg. Volume47,367
Market Cap705.581M
Beta (5Y Monthly)-0.49
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est36.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ENGN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • enGene Holdings Inc.
    Daily – Vickers Top Buyers & Sellers for 04/01/2024The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    9 days agoArgus Research
View more
  • CNW Group

    /C O R R E C T I O N -- enGene Inc./

    enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced that Raj Pruthi MD MHA FACS has joined the Company as SVP, Urologic Oncology and Clinical Development, reporting to enGene's Chief Medical Officer, Dr. Richard Bryce. In this role, Dr. Pruthi's responsibilities will include sup

  • PR Newswire

    enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress

    enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced its financial results for the first quarter ended January 31, 2024.

  • CNW Group

    enGene To Present at the Leerink Partners Global Biopharma Conference

    enGene Holdings Inc. (Nasdaq: ENGN) or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced that Jason Hanson, Chief Executive Officer, will present at the Leerink Partners Global Biopharma Conference in Miami, FL on March 13, 2024, at 8:40 a.m. ET.